Bio-Techne Corp has made a strong and impressive performance in Q2 2026, significantly beating earnings estimates, meeting revenue forecasts, and seeing a climb in Q2 profit. This has led to an increase in their price target by various institutions, such as Wells Fargo and Stifel. Citigroup also raised its price target to $80.00. This optimistic performance and outlook have also resulted in new investments in the firm. Despite its robust performance, there has been some selling of shares by Rep. April McClain Delaney and some companies. On the innovative front, the firm is expanding its 3D Stem Cell and Organoid Culture Portfolio with a fully Defined Synthetic Alternative, hinting at reducing animal use and boosting drug tests. This new approach could advance Automated 3D Multiomics Technology and Accelerate Spatial Biology. The most recent news reveals plans for BIO-TECHNE to launch ProximityScope™ Assay on the BOND RX platform from Leica Biosystems to Advance Spatial Protein-Protein Interactions Research, signaling plans for advanced multiplexing and high-throughput protein analysis.
Bio-Techne Corp TECH News Analytics from Wed, 25 Jun 2025 07:00:00 GMT to Fri, 06 Feb 2026 23:05:25 GMT -
Rating 8
- Innovation 9
- Rumor 3
